Press coverage about Midatech Pharma PLC (NASDAQ:MTP) has been trending somewhat negative on Thursday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Midatech Pharma PLC earned a coverage optimism score of -0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.2178149393176 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Midatech Pharma PLC (NASDAQ MTP) opened at 1.46 on Thursday. The firm’s 50-day moving average price is $1.78 and its 200-day moving average price is $2.42. The firm’s market capitalization is $35.56 million. Midatech Pharma PLC has a 12-month low of $1.29 and a 12-month high of $3.65.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

Midatech Pharma PLC Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Insider Buying and Selling by Quarter for Midatech Pharma PLC (NASDAQ:MTP)

Receive News & Stock Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related stocks with our FREE daily email newsletter.